These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30016661)

  • 1. A novel porcine model of thrombotic myocardial infarction with cardiac dysfunction sensitive to dual antiplatelet therapy.
    Mizuno M; Ito Y; Sugidachi A
    Eur J Pharmacol; 2018 Sep; 834():103-108. PubMed ID: 30016661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrel.
    Ohno K; Tomizawa A; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Res; 2015 May; 135(5):933-8. PubMed ID: 25776467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
    Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
    Garratt KN; Weaver WD; Jenkins RG; Pow TK; Mauri L; Kereiakes DJ; Winters KJ; Christen T; Allocco DJ; Lee DP
    Circulation; 2015 Jan; 131(1):62-73. PubMed ID: 25400062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
    Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
    Kou N; Xue M; Yang L; Zang MX; Qu H; Wang MM; Miao Y; Yang B; Shi DZ
    PLoS One; 2018; 13(3):e0194082. PubMed ID: 29584740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended duration dual antiplatelet therapy in patients with myocardial infarction: A study-level meta-analysis of controlled randomized trials.
    Patti G; Cavallari I
    Am Heart J; 2016 Jun; 176():36-43. PubMed ID: 27264218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study.
    Choi JH; Cho JR; Park SM; Shaha KB; Pierres F; Sumiya T; Chun KJ; Kang MK; Choi S; Lee N
    Yonsei Med J; 2017 Sep; 58(5):959-967. PubMed ID: 28792139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction.
    Kereiakes DJ; Yeh RW; Massaro JM; Cutlip DE; Steg PG; Wiviott SD; Mauri L;
    J Am Coll Cardiol; 2016 May; 67(21):2492-502. PubMed ID: 27046159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosis.
    Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
    Thromb Res; 2015 Dec; 136(6):1224-30. PubMed ID: 26388120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
    Sanganalmath SK; Barta J; Takeda N; Kumamoto H; Dhalla NS
    Can J Physiol Pharmacol; 2008 Apr; 86(4):180-9. PubMed ID: 18418427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective Effects of Ticagrelor on Myocardial Injury After Infarction.
    Vilahur G; Gutiérrez M; Casani L; Varela L; Capdevila A; Pons-Lladó G; Carreras F; Carlsson L; Hidalgo A; Badimon L
    Circulation; 2016 Nov; 134(22):1708-1719. PubMed ID: 27789556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
    Udell JA; Bonaca MP; Collet JP; Lincoff AM; Kereiakes DJ; Costa F; Lee CW; Mauri L; Valgimigli M; Park SJ; Montalescot G; Sabatine MS; Braunwald E; Bhatt DL
    Eur Heart J; 2016 Jan; 37(4):390-9. PubMed ID: 26324537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pre-procedural dual antiplatelet therapy on periprocedural myocardial infarction in patients undergoing percutaneous coronary interventions with adjunctive tirofiban.
    Verdoia M; Pergolini P; Barbieri L; Rolla R; Nardin M; Negro F; Suryapranata H; De Luca G;
    Thromb Res; 2018 Apr; 164():17-23. PubMed ID: 29475177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials.
    Fanari Z; Malodiya A; Weiss SA; Hammami S; Kolm P; Weintraub WS
    Cardiovasc Revasc Med; 2017; 18(1):10-15. PubMed ID: 27477306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panax quinquefolius saponins combined with dual antiplatelet therapy enhanced platelet inhibition with alleviated gastric injury via regulating eicosanoids metabolism.
    Wang W; Song L; Yang L; Li C; Ma Y; Xue M; Shi D
    BMC Complement Med Ther; 2023 Aug; 23(1):289. PubMed ID: 37596586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry.
    Schiele F; Puymirat E; Bonello L; Dentan G; Meneveau N; Collet JP; Motreff P; Ravan R; Leclercq F; Ennezat PV; Ferrières J; Berard L; Simon T; Danchin N
    Int J Cardiol; 2015; 187():354-60. PubMed ID: 25839641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.